ADM unveils supportive solutions for GLP-1 users
ADM introduces a new platform offering tailored nutritional solutions for consumers using GLP-1 and other anti-obesity medications. The initiative aims to address the unique dietary needs of this growing segment, as market projections for AOMs approach £100 billion by 2030.